Akebia Therapeutics (AKBA) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 37.0% versus a loss of 70.4%. Over five years, GLSI leads with a -59.5% price change compared with -69.4% for AKBA. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $222.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | GLSI |
|---|---|---|
| Share price | $0.8148 | $15.14 |
| Market cap | $225.79M | $222.23M |
| 1-day change | -6.71% | -1.62% |
| YTD return | -45.75% | -26.75% |
| 1-year return | -70.39% | +37.04% |
| 5-year return | -69.35% | -59.46% |
| EPS (TTM) | $-0.12 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $34.10 |
| 52-week low | $0.814 | $7.78 |
| Distance from 52-week high | -74.54% | -55.60% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.10% | +276.49% |
| Average volume | 6.13M | 138.72K |
| Shares outstanding | 277.11M | 14.68M |
| Employees | 194 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed AKBA by 107.4 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
AKBA vs GLSI FAQ
Which is bigger, Akebia Therapeutics or Greenwich LifeSciences?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $222.23M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, AKBA or GLSI?
GLSI returned +37.04% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.